According to the AUA, a patient with metastatic CRPC who has a poor performance status and has not been treated with docetaxel should be treated with an androgen synthesis inhibitor plus glucocorticoid or androgen receptor inhibitor. An immunotherapeutic agent, like sipuleucel-T, should not be offered. Monotherapy with a taxane, like docetaxel, is not recommended, but it can be combined with androgen synthesis inhibitor. Watchful waiting is recommended by the AUA for patients with low-risk or intermediate-risk localized prostate cancer and a life expectancy ≤ 5 years.
Learn more about the management of metastatic CRPC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Evelyn S. Marienberg. Fast Five Quiz: Castration-Resistant Metastatic and Advanced Prostate Cancer Management - Medscape - Nov 08, 2022.